The articles listed on this page are from a variety of sources. 
1. The staff of DBS-STN often attends conferences or educational opportunities both nationally and internationally, and a brief understandable write-up of the information presented at the event will be provided for our readers to review. 
2. DBS-STN staff also identifies or writes various articles related to topics that are thought to be of interest for the reader of www.DBS-STN.org. 

Browse by Topic:
Search:

Adamas Pharma (ADMS) Announces ADS-5102 Phase 3 Met Primary, Key Secondary Endpoints as LID Treatment


(April 29, 2016) - Adamas Pharmaceuticals, Inc.announced that its Phase 3 trial evaluating ADS-5102 (amantadine HCl) extended-release capsules for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease met its primary and key secondary endpoints. Read more…



Article Archive

back